Volume 73, Issue 3, Pages (March 2018)

Slides:

Advertisements

Similar presentations

The PSA Era is not Over for Prostate Cancer

Advertisements

Volume 52, Issue 1, Pages (July 2007)

Volume 60, Issue 2, Pages (August 2011)

Volume 52, Issue 1, Pages (July 2007)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Testosterone Therapy in Men With Prostate Cancer

Volume 58, Issue 5, Pages (November 2010)

Volume 56, Issue 6, Pages (December 2009)

Systematic Review of the Efficacy and Safety of High-Intensity Focussed Ultrasound for the Primary and Salvage Treatment of Prostate Cancer Marisa Warmuth,

Volume 53, Issue 4, Pages (April 2008)

Volume 74, Issue 2, Pages (August 2018)

Volume 51, Issue 4, Pages (April 2007)

Volume 70, Issue 4, Pages (October 2016)

Volume 49, Issue 5, Pages (May 2006)

Prostate Cancer Epidemic in Sight?

Volume 70, Issue 5, Pages (November 2016)

Failure to Achieve Castration Levels in Patients Using Leuprolide Acetate in Locally Advanced Prostate Cancer Olav Erich Yri, Trine Bjoro, Sophie D.

Volume 63, Issue 2, Pages (February 2013)

Volume 53, Issue 2, Pages (February 2008)

Volume 61, Issue 1, Pages (January 2012)

Volume 74, Issue 1, Pages (July 2018)

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Volume 65, Issue 3, Pages (March 2014)

Ute Ganswindt, Arnulf Stenzl, Michael Bamberg, Claus Belka

Volume 53, Issue 4, Pages (April 2008)

Prostate Cancer Detection: A View of the Future

Volume 66, Issue 3, Pages (September 2014)

Low-risk Prostate Cancer: Identification, Management, and Outcomes

Volume 69, Issue 6, Pages (June 2016)

Volume 55, Issue 3, Pages (March 2009)

Volume 73, Issue 6, Pages (June 2018)

Counselling the Prostate Cancer Patient

Prostate Cancer Epidemic in Sight?

The PSA Era is not Over for Prostate Cancer

Volume 61, Issue 5, Pages (May 2012)

Volume 74, Issue 3, Pages (September 2018)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 68, Issue 6, Pages (December 2015)

Leonard S. Marks, Jiaoti Huang European Urology

Volume 53, Issue 4, Pages (April 2008)

Volume 66, Issue 2, Pages (August 2014)

Volume 63, Issue 3, Pages (March 2013)

Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia

Is It Necessary to Detect All Prostate Cancers in Men with Serum PSA Levels

Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.

Two-years Postradiotherapy Biopsies: Lessons from MRC RT01 Trial

Volume 62, Issue 3, Pages (September 2012)

Volume 62, Issue 6, Pages (December 2012)

Volume 71, Issue 2, Pages (February 2017)

Volume 50, Issue 5, Pages (November 2006)

CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System

Volume 55, Issue 3, Pages (March 2009)

Volume 74, Issue 5, Pages (November 2018)

The Importance of Testosterone Control in Prostate Cancer

Volume 67, Issue 6, Pages (June 2015)

Testicular Cancer Variations in Time and Space in Europe

Volume 53, Issue 1, Pages (January 2008)

Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Cancer Amar U. Kishan, Rahul.

Volume 72, Issue 2, Pages (August 2017)

Volume 373, Issue 9660, Pages (January 2009)

Challenges and Opportunities in Hormone-Resistant Prostate Cancer

European Urology is “Your” Journal

Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders

Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration- resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary.

A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study John Fitzpatrick European.

Prostate Cancer Screening Decreases the Absolute Risk of Being Diagnosed with Advanced Prostate Cancer—Results from a Prospective, Population-Based Randomized.

Edith Canby-Hagino, Javier Hernandez, Timothy C. Brand, Ian Thompson

Volume 53, Issue 2, Pages (February 2008)

Manfred Wirth, Peter Iversen, David McLeod, William See

Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non–Muscle-Invasive Bladder Cancer Sten Holmäng European Urology.

Presentation transcript:

Volume 73, Issue 3, Pages 427-435 (March 2018) Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial Christopher C. Parker, Robert E. Coleman, Oliver Sartor, Nicholas J. Vogelzang, David Bottomley, Daniel Heinrich, Svein I. Helle, Joe M. O'Sullivan, Sophie D. Fosså, Aleš Chodacki, Paweł Wiechno, John Logue, Mihalj Seke, Anders Widmark, Dag Clement Johannessen, Peter Hoskin, Nicholas D. James, Arne Solberg, Isabel Syndikus, Jan Kliment, Steffen Wedel, Sibylle Boehmer, Marcos Dall’Oglio, Lars Franzén, Øyvind S. Bruland, Oana Petrenciuc, Karin Staudacher, Rui Li, Sten Nilsson European Urology Volume 73, Issue 3, Pages 427-435 (March 2018) DOI: 10.1016/j.eururo.2017.06.021 Copyright © 2017 European Association of Urology Terms and Conditions

Fig. 1 ALSYMPCA study timeline. ALSYMPCA=Alpharadin in Symptomatic Prostate Cancer; W=week; Y=year. European Urology 2018 73, 427-435DOI: (10.1016/j.eururo.2017.06.021) Copyright © 2017 European Association of Urology Terms and Conditions

Fig. 2 CONSORT diagram. a One patient in the placebo group received one injection of radium-223 (week 0) and is included in the radium-223 safety analysis. b Two (<1%) radium-223 and two (<1%) placebo patients’ study completion pages were not received. European Urology 2018 73, 427-435DOI: (10.1016/j.eururo.2017.06.021) Copyright © 2017 European Association of Urology Terms and Conditions